Terazosin now indicated for benign prostatic hyperplasia.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin